Literature DB >> 6228528

Echocardiographic left ventricular hypertrophy as related to arterial pressure and plasma norepinephrine concentration in arterial hypertension. Reversal by atenolol treatment.

L Corea, M Bentivoglio, P Verdecchia.   

Abstract

We tried to assess relationships between echocardiographic left ventricular hypertrophy (LVH), arterial pressure levels, and plasma norepinephrine concentration (NE) in 20 previously untreated stable hypertensive patients with LVH, and in 11 healthy normotensive control subjects. Interventricular septal (IVS) thickness, posterior wall (PW) thickness, and left ventricular mass index (LVMI) were related to arterial pressure levels and to NE by univariate and multivariate regression analyses. In addition, after 18 months of monotherapy with atenolol (carried out in nine of 20 patients), the relationship between echocardiographic changes and degree of pressure reduction was tested. Before treatment, PW thickness weakly correlated with systolic (r = 0.55; p less than 0.01) and mean (r = 0.50; p less than 0.05) arterial pressure. IVS thickness weakly correlated with NE (r = 0.53; p less than 0.05). On this relatively small sample, multivariate regression analysis showed an association of both IVS thickness (R = 0.57; p less than 0.05) and PW thickness (R = 0.58; p less than 0.05) with mean arterial pressure (MAP) and NE. After atenolol, there was a reduction in IVS thickness (1.15 to 1.02 cm; p less than 0.01), PW thickness (1.08 to 0.99 cm; p less than 0.01), and LVMI (136.3 to 113.8 g/m2; p less than 0.01), besides a significant reduction in blood pressure and heart rate. The degree of pressure reduction induced by treatment did not correlate the change in IVS or PW thickness. In contrast, the change in diastolic and mean arterial pressure positively correlated the change in LVMI (r = 0.72 and r = 0.75, respectively; both p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6228528     DOI: 10.1161/01.hyp.5.6.837

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  Cardiovascular reactivity in cardiovascular disease: "once more unto the breach".

Authors:  S B Manuck
Journal:  Int J Behav Med       Date:  1994

Review 2.  Atenolol. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disorders.

Authors:  A N Wadworth; D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-09       Impact factor: 9.546

3.  Mean arterial pressure values calculated using seven different methods and their associations with target organ deterioration in a single-center study of 1878 individuals.

Authors:  Theodore G Papaioannou; Athanase D Protogerou; Dimitrios Vrachatis; Giorgos Konstantonis; Evaggelia Aissopou; Antonis Argyris; Efthimia Nasothimiou; Elias J Gialafos; Marianna Karamanou; Dimitris Tousoulis; Petros P Sfikakis
Journal:  Hypertens Res       Date:  2016-05-19       Impact factor: 3.872

4.  Metformin Inhibits Isoproterenol-induced Cardiac Hypertrophy in Mice.

Authors:  Hye-Na Cha; Jung Hyun Choi; Yong-Woon Kim; Jong-Yeon Kim; Myun-Whan Ahn; So-Young Park
Journal:  Korean J Physiol Pharmacol       Date:  2010-12-31       Impact factor: 2.016

5.  Regression of left ventricular hypertrophy on long-term treatment with captopril of severe hypertensives refractory to standard triple treatment.

Authors:  U de Faire; K Lindvall; G Andersson; S Eriksson
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Left ventricular hypertrophy. Prevalence in older patients and management.

Authors:  E Paciaroni; A Fraticelli
Journal:  Drugs Aging       Date:  1995-04       Impact factor: 3.923

Review 7.  Ventricular dysrhythmias, left ventricular hypertrophy, and sudden death.

Authors:  F H Messerli; F Soria
Journal:  Cardiovasc Drugs Ther       Date:  1994-08       Impact factor: 3.727

8.  Myocardial hypertrophy, cardiac beta-adrenoceptors and adenylate cyclase activity during sinoaortic denervation in dogs.

Authors:  M Galinier; J M Sénard; P Valet; G Dréan; V Planat; A Arias; M A Tran; J L Montastruc
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

9.  Effect of beta-blockade on exercise capacity in hypertensive subjects: a one-year double-blind study of celiprolol and metoprolol.

Authors:  G P Vyssoulis; M T Kouremetis; M A Valiouli; A P Michaelides; P K Toutouzas
Journal:  Cardiovasc Drugs Ther       Date:  1995-02       Impact factor: 3.727

Review 10.  Left ventricular hypertrophy and antihypertensive therapy.

Authors:  F H Messerli; S Oren; E Grossman
Journal:  Drugs       Date:  1988       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.